Dr. Kiran K. Yalamanchili

Claim this profile

Covenant Medical Center-Lakeside

Studies Lung Cancer
Studies Cancer
6 reported clinical trials
30 drugs studied

Area of expertise

1Lung Cancer
Kiran K. Yalamanchili has run 3 trials for Lung Cancer. Some of their research focus areas include:
PD-L1 positive
Stage IV
ALK negative
2Cancer
Kiran K. Yalamanchili has run 2 trials for Cancer. Some of their research focus areas include:
Stage IV
p16 negative
EGFR positive

Affiliated Hospitals

Image of trial facility.
Covenant Medical Center-Lakeside
Image of trial facility.
Joe Arrington Cancer Research And Treatment Center

Clinical Trials Kiran K. Yalamanchili is currently running

Image of trial facility.

Chemotherapy + Radiation Therapy

for Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.
Recruiting1 award Phase 2 & 321 criteria
Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria

More about Kiran K. Yalamanchili

Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Kiran K. Yalamanchili has experience with
  • Atezolizumab
  • Cisplatin
  • Intensity-Modulated Radiation Therapy
  • Nivolumab
  • Ipilimumab
  • Lenvatinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kiran K. Yalamanchili specialize in?
Kiran K. Yalamanchili focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved PD-L1 positive patients, or patients who are Stage IV.
Is Kiran K. Yalamanchili currently recruiting for clinical trials?
Yes, Kiran K. Yalamanchili is currently recruiting for 2 clinical trials in Lubbock Texas. If you're interested in participating, you should apply.
Are there any treatments that Kiran K. Yalamanchili has studied deeply?
Yes, Kiran K. Yalamanchili has studied treatments such as Atezolizumab, Cisplatin, Intensity-Modulated Radiation Therapy.
What is the best way to schedule an appointment with Kiran K. Yalamanchili?
Apply for one of the trials that Kiran K. Yalamanchili is conducting.
What is the office address of Kiran K. Yalamanchili?
The office of Kiran K. Yalamanchili is located at: Covenant Medical Center-Lakeside, Lubbock, Texas 79410 United States. This is the address for their practice at the Covenant Medical Center-Lakeside.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.